Hook & thesis
United States Antimony (UAMY) has just gone through a painful price reset: shares fell to $2.67 on 11/16/2026 after a week of weak headlines and a revenue miss, yet trading volume remains elevated — today’s volume was roughly 6.05M vs. a two-week average near 6.06M. That combination - outsized liquidity with a clear break in price - can produce a sharp rebound when headline pressure eases and flows stabilize.
We recommend a tactical long - not a buy-and-forget position - sized as a swing trade over the next 45 trading days. Entry at $2.67 with a disciplined stop at $2.45 limits downside to roughly 8% while setting a target of $4.00 captures the likely mean-reversion toward the mid-term moving averages and a technical recovery. The trade is high-risk but offers attractive asymmetry: reward-to-risk here is near 6:1 if the company can steady volumes and benefit from pending defense-related demand.
What the company does and why the market should care
United States Antimony extracts and processes antimony, zeolite, and precious metals through four operating segments: U.S. Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and U.S. Zeolite Operations. The company occupies a unique position as one of the only major domestic antimony processors - a critical mineral for flame retardants, lead-acid batteries, and defense applications.
Market relevance here is two-fold. First, antimony is designated a critical mineral in the context of supply security; U.S. government demand and funding for near-shoring projects are a structural tailwind. Second, the stock is heavily traded and levered to short-term flows: short interest has been material (recent settlement ~38.7M shares with days-to-cover roughly six days), which amplifies volatility and creates the potential for sharp intraday moves when buyers return.
Key recent numbers
- Share price: $2.67 (current)
- Market cap: ~$398.7M
- Shares outstanding: ~149.33M; float ~135.30M
- 52-week range: $2.53 - $12.64 (low on 11/05/2026, high on 05/06/2026)
- Q3 results (reported 11/12/2026): loss of $0.06 per share; revenue $10.13M (missed estimates by ~40.6%)
- Operating cash flow: negative $20.7M for the first half of 2026 (management commentary)
- Balance sheet / liquidity: current ratio 4.66, quick ratio 2.83; cash figure flagged at $1.96 (per reported ratio item)
- Profitability & valuation metrics: EPS -$0.14 (TTM), price-to-sales ~10.53, EV-to-sales ~9.74, free cash flow -$68.29M
How this supports the trade
The immediate bullish case is technical and flow-driven. The stock is near its 52-week low ($2.53) after a 2026 pullback; the 10- and 21-day EMAs sit above current price (EMA9 ~ $2.97, EMA21 ~ $3.11), and RSI is below neutral (~40), leaving room for a bounce. MACD shows a small bullish histogram, suggesting short-term bullish momentum may be forming.
Fundamentally, UAMY remains a play on domestic critical-mineral supply and defense demand. Management completed DLA shipments and highlighted contractual orders in the tens of millions; the company reported completion of initial shipments (82,000 pounds generating ~$2.6M) and cited order flow of ~$57.3M across defense programs earlier in the year. If delivery cadence and antimony prices stabilize, revenue and cash flow trajectories could improve materially versus the lows, which would justify a re-rating from current depressed multiples.
Valuation framing
At a market cap near $398.7M and an enterprise value around $368.9M, UAMY is trading at elevated revenue multiples (price-to-sales ~10.5, EV-to-sales ~9.7) despite being unprofitable and negative on free cash flow (-$68.3M). Those multiples reflect scarce domestic supply and optionality tied to defense contracts, but they also embed higher expectations relative to current revenue run-rate. In short: the equity is priced for a narrative (securing long-term, higher-margin government business) rather than current earnings power.
That makes this a trade, not a fundamental value buy. A successful rebound requires improvement in sales cadence and working capital outcomes; absent that, the valuation premium is unjustified and downside risk remains.
Catalysts to watch (2-5)
- Government contract deliveries and timing - confirmation of follow-on shipments under DLA and Defense Logistics support will reduce uncertainty and prove order realization.
- Quarterly operational updates - sequential revenue improvement and better-than-feared delivery timing would be an immediate positive.
- Antimony price direction and China export policy - improving prices or renewed export curbs overseas would support margins.
- Any management action on capital allocation - a shift from buybacks to working capital or targeted capex could reassure markets after summer criticism over buybacks.
Trade plan (actionable)
We recommend a long trade with the following rules:
- Entry: buy at $2.67.
- Stop loss: $2.45. This sits below the nearby 52-week low ($2.53) and limits the downside to ~8% from entry.
- Target: $4.00. This is our mid-term technical target (about 50% upside) and sits above the 50-day moving average (~$3.72), allowing for a pullback/rotation back toward prior short-term support/resistance levels.
- Horizon: mid term (45 trading days). Expect the trade to play out over several weeks as order confirmations, shipment cadence, and short-covering dynamics unfold; do not treat this as an overnight scalp.
Position sizing: keep exposure modest given the company’s negative free cash flow and revenue misses. Consider taking profits incrementally at $3.50 and $4.00, and tighten stops if the stock breaks above $3.50 on strong volume to protect gains.
Risks & counterarguments
This trade is far from risk-free. Key risks include:
- Execution risk: The company has reported sequential revenue misses (Q3 revenue $10.13M missed consensus and Q2 sales were weak). Continued delivery timing issues or missed shipments would sink sentiment and revenue.
- Cash-flow & capital allocation: Operating cash flow was negative in early 2026 and free cash flow is deeply negative. Management previously authorized buybacks which drew criticism while liquidity remains constrained; further cash burn could force equity raises or scaled-back operations.
- Commodity-price and market risk: Antimony prices are volatile and tied to global supply/demand and Chinese policy. A renewed price slump or easing of export constraints overseas would reduce margin potential.
- High short interest and volatility: Elevated short interest means the stock can move violently in either direction; while that creates upside on short-covering, it also amplifies downside during negative news.
- Valuation disconnect: Current multiples assume a narrative recovery. If the company cannot convert orders into profitable cash flow, the market could re-rate the stock substantially lower.
Counterargument: Critics will point to the revenue misses, negative cash flow, and the company’s relatively high price-to-sales multiple as signs that UAMY is structurally overvalued. That is a valid view: without material improvements to cash generation or a firming of antimony prices, the stock can re-test and breach the 52-week low. This trade only works if supply/demand and delivery trajectories begin to normalize within the next several weeks.
Conclusion - stance and what would change my mind
Stance: Buy (swing). The ideal trade capitalizes on heavy volume-driven price weakness and a clear support area near the 52-week low. Entry at $2.67 with a $2.45 stop and a $4.00 target offers a compelling risk/reward for a 45-trading-day trade given the company’s unique position in domestic antimony supply and real, if uneven, government order flow.
What would change my mind: sustained revenue deterioration, further negative guidance, or new evidence that government orders will be delayed materially would invalidate the thesis. Conversely, a confirmed pick-up in shipments, better-than-expected quarterly results, or positive developments on antimony pricing would strengthen conviction and shift this from a tactical swing to a longer-term position.
Key metrics table
| Metric | Value |
|---|---|
| Current price | $2.67 |
| Market cap | $398.7M |
| EV | $368.9M |
| Price-to-sales | ~10.53 |
| Free cash flow (trailing) | -$68.3M |
| 52-week range | $2.53 - $12.64 |
Final note
This is a disciplined, tactical trade that relies on mean-reversion and update-driven execution. Size positions conservatively, set the stop at $2.45, and reassess if the company fails to show shipment execution or if cash-burn accelerates materially. If catalysts line up, the trade should reach the mid-term target within 45 trading days; if not, accept the stop and move on.